Compare GEF & PRAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GEF | PRAX |
|---|---|---|
| Founded | 1877 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.7B | 4.0B |
| IPO Year | N/A | 2020 |
| Metric | GEF | PRAX |
|---|---|---|
| Price | $65.46 | $247.81 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 4 | 13 |
| Target Price | $69.50 | ★ $239.62 |
| AVG Volume (30 Days) | 233.9K | ★ 1.0M |
| Earning Date | 11-05-2025 | 11-05-2025 |
| Dividend Yield | ★ 3.42% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $4,290,654,188.00 | $7,463,000.00 |
| Revenue This Year | $2.73 | N/A |
| Revenue Next Year | $1.70 | N/A |
| P/E Ratio | $3.38 | ★ N/A |
| Revenue Growth | N/A | ★ 364.98 |
| 52 Week Low | $48.23 | $26.70 |
| 52 Week High | $70.98 | $277.44 |
| Indicator | GEF | PRAX |
|---|---|---|
| Relative Strength Index (RSI) | 65.39 | 71.38 |
| Support Level | $65.12 | $171.20 |
| Resistance Level | $66.55 | $199.47 |
| Average True Range (ATR) | 1.32 | 17.03 |
| MACD | 0.33 | 1.31 |
| Stochastic Oscillator | 81.26 | 74.75 |
Greif Inc is a producer of industrial packaging products and services with manufacturing facilities located in many countries. It offers a comprehensive line of rigid industrial packaging products, such as steel, fiber, and plastic drums, rigid intermediate bulk containers, closure systems for industrial packaging products, transit protection products, water bottles and remanufactured and reconditioned industrial containers, and services, such as container life cycle management, blending, filling, logistics, warehousing, and other packaging services. The company operates in three reportable business segments including Global Industrial Packaging, Paper Packaging and Services, and Land Management. It operates in USA, Europe, Middle East, Africa and Asia and Other Americas.
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. The firm is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company has generated three clinical-stage product candidates, ulixacaltamide (formerly known as PRAX-944), vormatrigine (formerly known as PRAX-628), and relutrigine (formerly known as PRAX-562), as well as PRAX-020 which has been in-licensed by UCB Biopharma SRL, or UCB.